Dr Thomas Winder, Dr Andrea Sartore-Bianchi and Dr Yu Sunakawa discuss the Clinical Question: Biomarkers: when to test, what to test and what are the consequences?
Dr Thomas Winder, Dr Andrea Sartore-Bianchi and Dr Yu Sunakawa discuss the Clinical Question: Biomarkers: when to test, what to test and what are the consequences?
Dr Thomas Winder is board certified for haematology and medical oncology. Since January 2020 he has been Head of the Department for Haematology and Oncology at the University Teaching Hospital Feldkirch, Austria. In addition, since 2017 he has been President of the Swiss Tumor Molecular Institute in Zürich Switzerland. Dr Winder’s research focuses on molecular markers to individualize medical treatment of cancer patients. He achieved his expertise in internationally renowned laboratories at University of Southern California, Norris Comprehensive Cancer Center, Los Angeles and University Hospital Zürich, Switzerland. His research activity has been honoured by several national and international awards and high impact publications.
Optimising precision medicine for improved patient outcomes
A closer look at the evolving treatment landscape
Experts' insights on treatment strategies in ER+ metastatic breast cancer settings
Expert insights on multimodal treatment for intermediate hepatocellular carcinoma (HCC)
Best practices and interpretation of results in lung and ovarian cancer
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer